Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Navy veteran Michael Giardina told Anderson Cooper he was able to "let go" of trauma from his childhood during a psychedelic ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...

Part 2 of the study will investigate a single dose of BPL-003 in patients who are BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered ...

Now 29, Turner remembers the perspective that came to her in the months after she was crushed by that tree in Portland’s ...